Auro Laboratories [AUROLAB] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison
Auro Laboratories
BSE
Loading...
Suven Life Sciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Auro Laboratories wins in 11 metrics, Suven Life Sciences wins in 7 metrics, with 0 ties. Auro Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Auro Laboratories | Suven Life Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 145.29 | -28.31 | Suven Life Sciences |
| Price-to-Book Ratio | 3.32 | 41.36 | Auro Laboratories |
| Debt-to-Equity Ratio | 104.76 | 0.00 | Suven Life Sciences |
| PEG Ratio | -1.27 | -0.34 | Auro Laboratories |
| EV/EBITDA | 88.13 | -24.12 | Suven Life Sciences |
| Profit Margin (TTM) | 5.96% | 84.44% | Suven Life Sciences |
| Operating Margin (TTM) | -8.69% | -2,791.92% | Auro Laboratories |
| Return on Equity | 4.28% | -146.15% | Auro Laboratories |
| Return on Assets (TTM) | 1.86% | -118.91% | Auro Laboratories |
| Free Cash Flow (TTM) | $-180.54M | $-1.91B | Auro Laboratories |
| 1-Year Return | 2.63% | 49.21% | Suven Life Sciences |
| Price-to-Sales Ratio (TTM) | 8.64 | 632.35 | Auro Laboratories |
| Enterprise Value | $1.86B | $44.90B | Suven Life Sciences |
| EV/Revenue Ratio | 11.30 | 597.31 | Auro Laboratories |
| Gross Profit Margin (TTM) | 67.54% | 100.00% | Suven Life Sciences |
| Revenue per Share (TTM) | $26 | $0 | Auro Laboratories |
| Earnings per Share (Diluted) | $1.57 | $-8.45 | Auro Laboratories |
| Beta (Stock Volatility) | 0.20 | 0.78 | Auro Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Auro Laboratories vs Suven Life Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Auro Laboratories | -3.33% | -7.33% | -4.38% | -13.53% | -10.49% | -16.18% |
| Suven Life Sciences | 0.37% | 3.79% | -10.27% | -21.82% | 76.25% | 63.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Auro Laboratories | 2.63% | 189.75% | 185.44% | 1,208.61% | 4,390.84% | 3,637.29% |
| Suven Life Sciences | 49.21% | 215.69% | 329.98% | -26.12% | 600.33% | 3,806.72% |
News Based Sentiment: Auro Laboratories vs Suven Life Sciences
Auro Laboratories
News based Sentiment: NEGATIVE
September proved to be a difficult month for Auro Laboratories, with a significant drop in share price and continued revenue declines overshadowing the long-term optimistic projections. The company's financial struggles are evident, making it a high-risk investment, and the upcoming trading window closure suggests potential significant developments are on the horizon.
Suven Life Sciences
News based Sentiment: MIXED
October was a month of conflicting signals for Suven Life Sciences. While the company benefited from a positive pharmaceutical sector rally and maintained a debt-free status, it also reported continued quarterly losses and received a negative analyst rating. This creates a complex investment narrative with both potential opportunities and significant risks.
Performance & Financial Health Analysis: Auro Laboratories vs Suven Life Sciences
| Metric | AUROLAB | SUVEN |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.50B | ₹47.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 4,177 | 184,111 |
| 90 Day Avg. Volume | 6,853 | 150,383 |
| Last Close | ₹220.50 | ₹209.40 |
| 52 Week Range | ₹170.00 - ₹303.00 | ₹102.50 - ₹299.99 |
| % from 52W High | -27.23% | -30.20% |
| All-Time High | ₹307.20 (May 06, 2024) | ₹338.50 (Apr 13, 2015) |
| % from All-Time High | -28.22% | -38.14% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.52% | 0.86% |
| Quarterly Earnings Growth | -0.52% | 0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.84% |
| Operating Margin (TTM) | -0.09% | -27.92% |
| Return on Equity (TTM) | 0.04% | -1.46% |
| Debt to Equity (MRQ) | 104.76 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹68.67 | ₹5.04 |
| Cash per Share (MRQ) | ₹1.02 | ₹2.75 |
| Operating Cash Flow (TTM) | ₹74.16M | ₹-1,590,282,000 |
| Levered Free Cash Flow (TTM) | ₹18.39M | ₹-1,607,450,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Auro Laboratories vs Suven Life Sciences
| Metric | AUROLAB | SUVEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 145.29 | -28.31 |
| Forward P/E | N/A | 10.78 |
| PEG Ratio | -1.27 | -0.34 |
| Price to Sales (TTM) | 8.64 | 632.35 |
| Price to Book (MRQ) | 3.32 | 41.36 |
| Market Capitalization | ||
| Market Capitalization | ₹1.50B | ₹47.99B |
| Enterprise Value | ₹1.86B | ₹44.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 11.30 | 597.31 |
| Enterprise to EBITDA | 88.13 | -24.12 |
| Risk & Other Metrics | ||
| Beta | 0.20 | 0.78 |
| Book Value per Share (MRQ) | ₹68.67 | ₹5.04 |
Financial Statements Comparison: Auro Laboratories vs Suven Life Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AUROLAB | SUVEN |
|---|---|---|
| Revenue/Sales | ₹27.74M | ₹18.67M |
| Cost of Goods Sold | ₹9.01M | ₹0 |
| Gross Profit | ₹18.74M | ₹18.67M |
| Research & Development | N/A | ₹414.88M |
| Operating Income (EBIT) | ₹-2.41M | ₹-521.17M |
| EBITDA | ₹4.49M | ₹-501.49M |
| Pre-Tax Income | ₹-1.06M | ₹-515.17M |
| Income Tax | ₹0 | ₹0 |
| Net Income (Profit) | ₹-1.06M | ₹-515.17M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AUROLAB | SUVEN |
|---|---|---|
| Cash & Equivalents | ₹3,000 | ₹150.26M |
| Total Current Assets | ₹215.14M | ₹754.72M |
| Total Current Liabilities | ₹216.42M | ₹234.86M |
| Long-Term Debt | ₹330.85M | N/A |
| Total Shareholders Equity | ₹429.68M | ₹1.10B |
| Retained Earnings | ₹359.52M | ₹-6.01B |
| Property, Plant & Equipment | ₹16.55M | ₹756.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AUROLAB | SUVEN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AUROLAB | SUVEN |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 4,177 | 184,111 |
| Average Daily Volume (90 Day) | 6,853 | 150,383 |
| Shares Outstanding | 6.23M | 218.07M |
| Float Shares | 2.50M | 67.61M |
| % Held by Insiders | 0.60% | 0.69% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Auro Laboratories vs Suven Life Sciences
| Metric | AUROLAB | SUVEN |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |